Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in PIQ?
Proteomics International Laboratories: THE INVESTMENT CASE

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions

Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
Richard Lipscombe, MD, Proteomics International Laboratories

Proteomics International Laboratories (ASX:PIQ) managing director, Richard Lipscombe, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

Proteomics is a revenue generating company holding the unique position as having the world's first diagnostic test at a commercialisation stage.

The company has proven technology with patents granted, with an Asian focus and global reach.


Register here to be notified of future PIQ Company articles
View full PIQ profile View Profile

Proteomics International Laboratories Timeline

Related Articles

generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use